Background {#Sec1}
==========

Nontyphoidal salmonellosis is a major zoonotic disease that most often causes gastroenteritis, but invasive infections can also occur and can be severe and life-threatening \[[@CR1]\]. The elderly, infants and immunocompromised patients are more likely to have a severe illness. It has been pointed out that strains belonging to some serovars (Heidelberg or Dublin) or to some multidrug resistant epidemic clones such as the widespread *Salmonella* Typhimurium DT104 are probably more virulent \[[@CR1]\]. A few in vitro studies suggest that the virulence in this penta-resistant clone is linked to the presence of a 43 kb integrative mobilizable element called *Salmonella* genomic island 1 (SGI1) \[[@CR2], [@CR3]\]. This element is made of a backbone and a multidrug resistance (MDR) region containing a cluster of genes responsible for the penta-resistance profile (ampicillin, chloramphenicol/florfenicol, streptomycin/spectinomycin, sulphonamides and tetracycline (ACSSuT)) \[[@CR4]\]. SGI1 has been reported in various serovars including serovars Agona, Infantis, Kentucky, Paratyphi B variant Java, and so on \[[@CR5]\]. Moreover many variants (SGI1-A to Z), in particular variants of the MDR region with other resistance genes, have been described, as well as a related genomic island, called *Proteus* genomic island 1 (PGI1) \[[@CR5]--[@CR13]\]. PGI1 has been notably reported in *S*. Heidelberg \[[@CR13]\]. SGI1 is usually integrated at the 3'end of the *thdF* chromosomal gene of *Salmonella enterica* but it is sometimes inserted in a secondary chromosomal attachment site at the 3′ end of the *sodB* gene \[[@CR14]\]. The prevalence of SGI1 in *S. enterica* is still unknown. Indeed, several studies have searched for the presence of SGI1 in collections of *S. enterica* strains selected according to their antimicrobial resistance or the presence of a class 1 integron or the serovar and therefore probably underestimated the prevalence of SGI1 because some SGI1 variants have no class 1 integron or MDR region \[[@CR15], [@CR16]\]. A Dutch study searched for the presence of a class 1 integron in 114 human strains of *S*. *enterica* and then searched for SGI1 in strains carrying a class 1 integron. They detected 9/114 (7.9%) isolates with SGI1 \[[@CR17]\]. Another study detected 17 SGI1-positive isolates out of 90 isolates (19%) selected by their penta-resistance and the presence of a class 1 integron among 1920 isolates from an international collection \[[@CR18]\]. A French study detected 16 SGI1 out of 28 (57%) human isolates of *S*. Typhimurium \[[@CR19]\]. During the epidemic period (1990--2004) of *S*. Typhimurium DT104 in Scotland, the median prevalence of isolates not containing SGI1, estimated using a Bayesian approach, was 4% in humans \[[@CR20]\]. The observation of severity illness in humans or in animals infected with the penta-resistant *S.* Typhimurium DT104 suggests that this clone is potentially more virulent \[[@CR21], [@CR22]\]. Several authors observed that SGI1 has a potential role in virulence by modulating expression of *S. enterica* genes, which could lead to hyper invasiveness \[[@CR2], [@CR23]\]. Other authors suggested that antimicrobial resistance increased severe of salmonellosis. One study observed that people were more likely to die after penta-resistant *S*. Typhimurium infection than were those with a pansusceptible *S*. Typhimurium infection \[[@CR24]\]. Two other studies showed that the hospitalization rate was higher in patients with a resistant *S.* Typhimurium \[[@CR25], [@CR26]\].

The present study has been driven by the observation in our hospital of 2 severe cases of invasive infections due to SGI1-positive *S.* Typhimurium DT104. A 15-year-old immunocompromised boy receiving corticoids and tacrolimus after hematopoietic stem-cells transplantation (acute leukemia) developed bacteremia. Despite a treatment with ceftriaxone 4 g/day during 21 days a septic arthritis of the shoulder occurred 15 days after stopping antibiotic. The second case was a 12-year-old immunocompetent boy who developed a collapsus after severe diarrhea and vomiting caused by *S.* Typhimurium DT104.

Here, a retrospective study was conducted in our hospital to investigate whether SGI1-positive *S. enterica* cause more severe illness than those without SGI1. A second objective was to establish whether antimicrobial resistance has an impact on severity of the illness.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

From 2011 to 2016, all patients infected by nontyphoidal *S. enterica* in our hospital were retrospectively included. When the isolate was not preserved in our laboratory, the patient was excluded. Clinical and biological data were retrospectively collected in medical records: age, sex, immunocompetence status, presence of invasive *S. enterica* infection (focal infections at systemic sites and/or bacteremia), sepsis, inflammatory response (hyperleucocytosis or increased CRP), presence of leukocytes and blood in stool, intravenous rehydration required. Patients were considered immunocompromised if they had underlying malignancies, HIV, receiving immunosuppressive treatments or suffering from sickle cell disease.

Identification of isolates and phage-typing {#Sec4}
-------------------------------------------

Isolates were identified by biochemical tests using Api20E, Biomerieux®. They were serotyped using the agglutination method with *Salmonella* poly and monovalent sera, Biorad® according to internationally standardized methods based on the Kauffman-White scheme*.* In the absence of corresponding sera in our laboratory, isolates were serotyped by the French National Reference Center *Salmonella.* For *S.* Typhimurium isolates, the phage-type DT104 was screened by PCR as previously described \[[@CR27]\].

Susceptibility to antimicrobial agents {#Sec5}
--------------------------------------

Susceptibility to antimicrobial agents was tested using the disk diffusion method on Mueller-Hinton agar in accordance with the CASFM- EUCAST guidelines of the year when the *S. enterica* was isolated. Antimicrobial profiles (susceptible or resistant) were retrospectively collected. The following antimicrobial agents were tested: amoxicillin, amoxicillin-clavulanic acid, ticarcillin, ticarcillin-clavulanic acid, piperacillin, piperacillin-tazobactam, cefotaxime, ceftazidime, cefepime, aztreonam, imipenem, nalidixic acid, ofloxacin, chloramphenicol, kanamycin, spectinomycin, streptomycin, tobramycin, amikacin, gentamicin, sulphonamides, trimethoprim and doxycycline.

Detection of SGI1 {#Sec6}
-----------------

Each nontyphoidal *S. enterica* isolate was screened for the presence of SGI1 by PCR targeting S026. This gene is highly conserved. To date, only one SGI1 variant without S026 (SGI1-Z) has been reported \[[@CR11]\]. This powerful method detects all genomic islands (SGI1 or PGI1) whatever their chromosomal location, as previously described \[[@CR13], [@CR28]\]. To screen for the S026 gene, a bacterial DNA template was prepared by the heat lysis of cells. PCR amplifications were carried out with 200 μM deoxynucleoside triphosphates, 1.5 mM MgCl~2~, 0.25 μM of each set of primers (S026 F and S026 R), 1 U of *Taq* DNA polymerase (ThermoScientific®) and 1 μL of bacterial DNA. PCR amplifications were performed in a T3 thermal cycler, as follows: initial denaturation at 94 °C for 10 min; 30 cycles of denaturation at 94 °C for 1 min, primer annealing at 50 °C for 1 min and extension at 72 °C for 1.5 min; and a final extension at 72 °C for 10 min (Additional file [1](#MOESM1){ref-type="media"}).

To determine the type of genomic island, two PCR amplifications were performed on the DNA template of each positive strain with a set of specific primers (S005 R- S010 F) to detect SGI1 and with a set of specific primers (C1596 R - C1594 outF2) to detect PGI1 (Additional file [1](#MOESM1){ref-type="media"}). PCR amplifications were carried out with 300 μM deoxynucleoside triphosphates, 1.5 mM MgCl~2~, 0.25 μM of each set of primers, 1 U of *Taq* DNA polymerase (ThermoScientific®) and 1 μL of bacterial DNA. PCR amplifications were performed in a Biometra T3 thermal cycler, as follows: initial denaturation at 94 °C for 10 min; 35 cycles of denaturation at 94 °C for 1 min, primer annealing at 50 °C for 1 min 30 and extension at 72 °C for 7 min; and a final extension at 72 °C for 10 min.

Statistical analysis {#Sec7}
--------------------

Univariate analysis:

Data were analyzed using a Kruskal-Wallis test to compare quantitative variables as medians for age or the length of hospital stay in days. Fisher's exact test was used to compare qualitative data. *P*-values \<0.05 were considered statistically significant.Multivariate analysis:

Relationships between the presence of SGI1 and illness severity or between the presence of antimicrobial resistance and illness severity or the determination of risk factors of invasive infections were modeled using a logistic multiple regression model. A robust variance estimator was used and linearity was checked using fractional polynomials. Goodness of fit of the logistic model was assessed through the Homer-Lemeshow statistic.

Statistical analysis was performed with Stat software (Stat Version14).

Results {#Sec8}
=======

Proportion and characteristics of SGI1-positive nontyphoidal S. Enterica {#Sec9}
------------------------------------------------------------------------

From 2011 to 2016, 122 patients were included. Twenty-two patients were excluded because their isolates were not preserved. Twenty-two different serovars were detected by serotyping among the 100 isolates. Twelve (12%) patients were infected by SGI1-positive nontyphoidal *S. enterica*. No isolates harbored PGI1. The SGI1-positive isolates belonged to 4 serovars: *S*. Typhimurium, *S*. Infantis, *S*. Kentucky and *S.* St Paul. The SGI1-positive isolates belonged mainly to serovar Typhimurium (7 isolates) (Table [1](#Tab1){ref-type="table"}). Moreover, the presence of SGI1 was significantly associated to the phage type DT104 (*p* = 0.001) (Table [2](#Tab2){ref-type="table"}). Likewise, there was a link between penta-resistance (ACSSuT) and the presence of SGI1 (*p* \< 0.001): two thirds of penta-resistant isolates were SGI1-positive. Despite the fact that history of recent travel was mostly not mentioned in medical records, it has to be noticed that four patients just coming back from Morocco were infected by SGI1-positive isolate: 2 belonging to serovar St-Paul and 2 belonging to serovar Kentucky.Table 1Characteristics of the strains isolated from patients infected by nontyphoidal *S. enterica*SerovarsSGI1-positive n (%)SGI1-negative n (%)*S.* Typhimurium (*n* = 36)7 (19.4)29 (80.6) DT104 (*n* = 9)5 (55.6)4 (44.4) Non DT104 (*n* = 27)2 (7.4)25 (92.6)Non *S*. Typhimurium serovars (*n* = 64)5 (7.8)59 (92.2)  *S*. 4, \[[@CR5]\], 12: i- (*n* = 19)019 (100)  *S*. Enteritidis (*n* = 14)014 (100)  *S*. Paratyphi B var. Java (*n* = 2)02 (100)  *S.* Dublin (*n* = 5)05 (100) Other serovars^a^ (*n* = 24)5^b^ (20.8)19 (79.2)Phenotypes^c^SGI1-positive n (%)SGI1-negative n (%)Pansusceptible (*n* = 21)0 (0)21 (100)Resistant ≥1 (*n* = 79)12 (15.2)67 (84.8)Including penta-resistant (ACSSuT)^d^ (*n* = 9)6 (67)3 (33)^a^Other serovars (*n* = 24): *S*. Ahmadi (*n* = 1). *S*. Braenderup (*n* = 1). *S*. Chester (*n* = 2). *S.* Eastbourne (*n* = 1). *S*. Eboko (*n* = 1). *S*. Hadar (*n* = 1). *S*. Hessarek (*n* = 2); *S*. Infantis (*n* = 2); *S*. Kedougou (*n* = 1); *S*. Kentucky (n = 2); *S*. Napoli (*n* = 1); *S*. Panama (*n* = 1); *S*. Rissen (*n* = 1); *S*. Schwarzengrund (*n* = 2); *S*. Singapore (*n* = 1); *S*. St Paul (*n* = 3); and a new variant: 6, 7, − (n = 1)^b^Other serovars with SGI1 (*n* = 5): *S*. Infantis (n = 1), *S*. Kentucky (n = 2), *S*. St Paul (n = 2)^c^Phenotype was determined by testing amoxicillin, amoxicillin -- clavulanic acid, ceftriaxone, nalidixic acid, chloramphenicol, kanamycin, spectinomycin, streptomycin, sulphonamides, trimethoprim and doxycycline in accordance to the antibiomicrobial guidelines of CASFM- EUCAST^d^ACSSuT: Amoxicillin, Chloramphenicol, Streptomycin, Sulphonamides and Tetracyclines Table 2SGI1 and severity of the illness: comparison of clinical and biological data^a^VariablesSGI1-positiveSGI1-negativep-value^c^N1288Age (years)13.9 (56.9)18.4 (54.2)*p* = 0.62Sex ratio M/F5/742/46*p* = 0.77Immunosuppression2 (16.7)15 (17.0)*p* = 1.00Invasive infection2 (16.7)13 (14.8)*p* = 1.00Bacteremia2 (16.7)10 (11.4)*p* = 0.63Sepsis2 (16.7)13 (14.8)*p* = 1.00Fever or hypothermia5 (41.7)53 (63.9)*p* = 0.21 Missing^b^05Inflammatory response11 (100)71 (96.0)*p* = 1.00 Missing^b^114Bloody stool2 (16.7)20 (23.5)*p* = 0.73 Missing^b^03Leukocytes in stool2 (16.7)36 (43.9)*p* = 0.11 Missing^b^06Intravenous hydration required5 (45.5)41 (65.1)*p* = 0.31 Missing^b^125Length of hospital stay in days2.5 (5)4 (6)*p* = 0.39Infection with Serovar Typhimurium7 (58.3)29 (33.0)*p* = 0.11 DT104 phage type5 (41.6)4 (4.5)*p* = *0.001*Infection with *S. enterica* harboring at least 1 resistance12 (100)67 (76.1)*p* = 0.07Infection with *S. enterica* harboring penta -- resistance (ACSSuT)^d^6 (50)3 (3.4)*p* \< *0.001*^a^Data are presented as median (interquartile range) for age and for long out of stay in hospital days or number of patients n (%)^b^Missing refers to data not available in medical records^c^Fisher's exact test and Kruskal-Wallis test were performed as appropriate and p-values \<0.05 were considered statistically significant^d^ACSSuT: Amoxicillin, Chloramphenicol, Streptomycin, Sulphonamides and TetracyclinesNumber italicized were statically significant

SGI1 and severity of the illness {#Sec10}
--------------------------------

From the clinical point of view, infections due to SGI1-positive isolates were not more severe than those due to isolates without SGI1. The relationship between the presence of SGI1 and invasive infection, bacteremia and sepsis was not statistically significant (Table [2](#Tab2){ref-type="table"}). There was also no difference after performing multivariate analysis adjusted for age, sex and immunocompetence status. Corresponding adjusted Odds Ratios (aOR) were: 1.35 (CI~95%~ 0.31--5.86) for invasive infection, 1.82 (CI~95%~ 0.39--8.46) for bacteremia, 1.28 (CI~95%~ 0.21--7.68) for sepsis.

Impact of antimicrobial resistance on the severity of illness {#Sec11}
-------------------------------------------------------------

The rate of isolates fully susceptible to all antimicrobial classes was 21% (Table [3](#Tab3){ref-type="table"}). Concerning an eventual link between antimicrobial resistance and severity of the illness it was surprising to notice that patients infected with a resistant isolate (harboring SGI1 or not) developed significantly less bacteremia (7.6%) than those infected with pansusceptible *S. enterica* (28.6%; *p* = 0.02) (Table [4](#Tab4){ref-type="table"}). This result was confirmed by multivariate analysis adjusted for age, sex and immunocompetence status \[adjusted Odds ratio (aOR) = 0.10 (CI~95%~: 0.02--0.55)\]. Invasive infections \[aOR = 0.16 (CI~95%~: 0.03--0.72)\], and sepsis \[aOR = 0.20 (CI~95%~: 0.05--0.80)\] were also significantly less frequent in patients infected with a resistant isolate.Table 3Epidemiology of antimicrobial resistance in nontyphoidal *S. enterica* strains ^a^AntibioticsPercentage of resistanceAmoxicillin37Amoxicillin --clavulanic acid17Cefotaxime2Nalidixic acid9Ofloxacin9Kanamycin3Streptomycin49Spectinomycin13Sulphonamides52Trimethoprim9Chloramphenicol12Doxycycline61^a^Antimicrobial susceptibility testing was determined in accordance to the antimicrobial guidelines of CASFM-EUCAST Table 4Antimicrobial resistance and severity of illness: comparison of clinical and biological dataVariablesInfection with pansusceptible isolate^a^ (*n* = 21)Infection with isolate harboring at least 1 resistance^a^ (*n* = 79)Univariate analysis *p*-value^b^Age (years)22.3 (53.7)15.8 (54)0.26Sex ratio (H/F)12/935/440.28Immunosuppression1 (4.8)16 (20.3)0.11Invasive infection6 (28.6)9 (11.4)0.08Bacteremia6 (28.6)6 (7.6)*0.02*Sepsis6 (28.6)9 (11.4)0.08Inflammatory response19 (100)63 (95.5)1.00 Missing^c^213Fever or hypothermia13 (65)45 (60)0.80 Missing^c^14^a^Data are presented as median (interquartile range) for age or number of patients n (%)^b^Fisher's exact test and Kruskal-Wallis test were performed as appropriate and p-values \<0.05 were considered statistically significant^c^Missing refers to data not available in medical recordsNumber italicized were statically significant

Risk factors to develop nontyphoidal *S. enterica* invasive infections {#Sec12}
----------------------------------------------------------------------

Patients developing invasive infection, sepsis and an inflammatory response were older than other patients (55.6 versus (vs) 12.7 years old, *p* = 0.03; 57.1 vs 12.7 years old, *p* = 0.01 and 24.3 vs 2.6 years old, *p* = 0.04, respectively) (Table [5](#Tab5){ref-type="table"}). In our study, five patients had underlying malignancies: one pancreatic cancer, one diffuse large B-cell lymphoma, one kidney cancer and two acute myeloid leukemias. Nine patients were received immunosuppressive treatment: infliximab for a Crohn's disease (one case); mesalazine for a Crohn's disease (one case); corticoid therapy for ulcerative colitis (one case); or multiple sclerosis (one case) or back pain following spinal arthrodesis (one case), corticoids and mycophenolate for a kidney transplant (one case), ciclosporine, corticoids and mycophenolate for a kidney transplant (one case), tacrolimus and everolimus for a liver transplant (one case), mycophenolate for lupus (one case). One patient, who also had lung cancer, was receiving everolimus, ciclosporine and corticoids for a heart transplant. Two patients were suffering from sickle-cell disease. As expected, the 17 immunocompromised patients had significantly more invasive infection (41.2% vs 9.6%, *p* = 0.003), bacteremia (29.4% vs 8.4%, *p* = 0.03) and sepsis (35.3% vs 10.8%, *p* = 0.02) than immunocompetent patients (Table [6](#Tab6){ref-type="table"}) \[[@CR1]\]. They were also significantly older than immunocompetent patients (54.2 vs 9.7 years old, *p* = 0.02). This observation was confirmed by multivariate analysis, except for bacteremia (aOR = 4.17 (CI~95%~: 0.99--17.57)). Indeed, immunocompromised patients developed more invasive infections \[aOR = 6.30 (CI~95%~: 1.62--24.46)\] and sepsis \[aOR = 3.79 (CI~95%~: 1.03--13.91\] than immunocompetent patients (*n* = 83).Table 5Age of patients and severity of illness: comparison of clinical and biological dataVariables (n: number of patients)Median age^a^iqr^a^*p*-value^b^Invasive infection No (*n* = 85)12.753.5*p* = *0.03* Yes (*n* = 15)55.661.4Bacteremia No (*n* = 88)15.553.6*p* = 0.08 Yes (*n* = 12)43.164.6Sepsis No (*n* = 85)12.748.8*p* = *0.01* Yes (*n* = 15)57.146.1Fever or hypothermia No (*n* = 37)2958*p* = 0.24 Yes (*n* = 58)9.151.7Inflammatory response No (*n* = 3)2.61.7*p* = *0.04* Yes (*n* = 82)24.356.6^a^Data are presented in years^b^Kruskal - Wallis test was performed and p-values \<0.05 were considered statistically significantNumber italicized were statically significant Table 6Host immunocompetence and severity of illness: comparison of clinical and biological dataVariablesImmmunosuppression^a^*p*-value^c^Yes (*n* = 17)No (*n* = 83)Age (years)54.2 (35.7)9.7 (54.4)*p* = *0.02*Invasive infection7 (41.2)8 (9.6)*p* = *0.003*Bacteremia5 (29.4)7 (8.4)*p* = *0.03*Sepsis6 (35.3)9 (10.8)*p* = *0.02*Fever or hypothermia7 (50.0)51 (63.0)*p* = 0.39 Missing^b^32Inflammatory response16 (100)66 (95.7)*p* = 1.00 Missing^b^114^a^Data are presented as median (interquartile range (IQR) for age or number of patients n (%)^b^Missing refers to data not available in medical records^c^Fisher's exact test and Kruskal-Wallis test were performed as appropriate and *p*-values \<0.05 were considered statistically significantNumber italicized were statically significant

Discussion {#Sec13}
==========

Our study is the first to evaluate the prevalence of clinical isolates of *S. enterica* harboring SGI1 without selection criteria. In our work, we detected SGI1 among various serovars and for the first time in serovar St Paul from 2 patients with a recent history of travel in Morocco. We observed a relatively high rate of 12% of SGI1-positive isolates. This rate is similar to the rate in a Dutch study (7.6%) \[[@CR17]\]. Other studies estimated higher rates, probably due to selection on the antimicrobial resistance of isolates. In an Australian study, Levings et al. reported eight SGI1-positive isolates (20.5%) among a collection of 39 clinical strains harboring at least one resistance \[[@CR29]\]. Krauland et al.*,* observed 17 SGI1-positive isolates (19%) among 90 penta-resistant isolates with a class 1 integron from a collection of 1920 international isolates \[[@CR18]\]. Although, two thirds of penta-resistant isolates were SGI1-positive in our study, our results demonstrated that the penta-resistance (ACSSuT) was not a specific and sensitive marker of SGI1 since only half of the isolates carrying SGI1 harbored this profile in our study. As previously described, most SGI1-positive isolates belonged to the serovar *S*. Typhimurium (13/17, 76.4%) \[[@CR18]\]. Finally, we confirmed the strong link between SGI1-positive *S*. Typhimurium and the DT104 phage-type (*p* = 0.001). A French study reported that 138 of 143 isolates of SGI1-positive *S*. Typhimurium (96.5%) belonged to the DT104 phage-type \[[@CR30]\].

The resistant profile of our isolates was slightly different from the French data reported in the European report of EFSA in 2014 \[[@CR31]\]. In our study the rate of resistance to nalidixic acid was much lower (9% vs 30%) and rates of resistance to amidinopenicillin, cyclines and sulphonamides were higher (37% vs 29.1%, 61% vs 40% and 52% vs 38% respectively). From the clinical point of view some of our results confirmed previous observations: elderly patients and immunocompromised patients were more likely to develop invasive nontyphoidal *S. enterica* infections \[[@CR1]\]. Surprisingly we observed that patients infected by nontyphoidal *S. enterica* harbouring at least one resistance developed less invasive nontyphoidal *S. enterica* infections than those infected by pansusceptible isolates. This is not in accords with previous reports which describe an excess of mortality in Danish population or increase in burden of illness in Canadian population infected by multidrug resistant *S*. Typhimurium \[[@CR24], [@CR25]\]. Nevertheless, in a review of the literature on studies using chicken, mice and nematodes, Andersson et al.*,* reported that antimicrobial resistance of *S.* Typhimurium has a fitness cost that is typically observed as a reduced bacterial growth rate \[[@CR32]\]. This might explain our observation. Concerning the impact of the SGI1 in virulence, our results did not confirm in vitro studies published to date. In previous reports, it was observed that SGI1 induced hyper invasiveness after exposure to rumen protozoa, partly due to S013 \[[@CR2], [@CR33], [@CR34]\]. Other authors showed that collagenase mediated cytopathic effect without repression by the SlyA protein in the presence of SGI1 \[[@CR22], [@CR35]\]. Moreover Sahu et al.*,* underlined that the MDR region of. *S.* Typhimurium DT104 plays a direct role in virulence against *Caenorhabditis elegans* \[[@CR3]\]. Finally, Golding et al. observed that the presence of SGI1 modulated the expression of *Salmonella* genes \[[@CR23]\]. To date no study has been conducted in humans. In our study, we did not observe any difference in severity of illness between patients infected by SGI1-positive nontyphoidal *S. enterica* and those infected by SGI1-negative isolates. However, our work is a preliminary study and it should be interesting to confirm this result in a larger study.

Conclusions {#Sec14}
===========

In this study, a *Salmonella* genomic island 1 has been detected in 12% of human clinical isolates belonging to various serovars and harbouring various antimicrobial resistance profiles. It might reflect a wide distribution of SGI1 among humans and probably also in animal isolates. Diseases due to SGI1-positive *S. enterica* or to antimicrobial resistant isolates were not more severe than the others. This first clinical observation should be confirmed by a multicenter and prospective study.
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ACSSuT

:   Ampicillin, chloramphenicol/florfenicol, streptomycin/spectinomycin, sulphonamides and tetracycline

aOR

:   Adjusted odds ratio

CASFM- EUCAST

:   Comité de l'Antibiogramme de la Société Française de Microbiologie -- European Committee on antimicrobial susceptibility testing

EFSA

:   European food safety authority

MDR

:   multidrug resistant

SGI1

:   *Salmonella* Genomic Island 1

Vs

:   Versus
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